Evidence map›Paper›PMID 32128254›Full record

ArticleNPJ vaccines2020

Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin.

Chad J Roy, Greta Van Slyke, Dylan Ehrbar, Zachary A Bornholdt, Miles B Brennan, Lioudmila Campbell, Michelle Chen, Do Kim, Neil Mlakar, Kevin J Whaley and 7 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Chad J Roy1Tulane National Primate Research Center, Covington, LA 70433 USA.
Greta Van Slyke2Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208 USA.
Dylan Ehrbar2Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208 USA.ORCID 0000-0001-7872-3338
Zachary A Bornholdt3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Miles B Brennan3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Lioudmila Campbell3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Michelle Chen3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Do Kim3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Neil Mlakar3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Kevin J Whaley3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Jeffrey W FroudeClinical Pharmacology Branch, Walter Reed Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
Fernando J Torres-Velez2Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208 USA.
Ellen Vitetta5Departments of Immunology and Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA.
Peter J Didier1Tulane National Primate Research Center, Covington, LA 70433 USA.
Lara Doyle-Meyers1Tulane National Primate Research Center, Covington, LA 70433 USA.
Larry Zeitlin3Mapp Biopharmaceutical, Inc, San Diego, CA 92121 USA.
Nicholas J Mantis2Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208 USA.ORCID 0000-0002-5083-8640
Mapp Biopharmaceutical (United States) · USNew York State Department of Health · USTulane University · USDefense Threat Reduction Agency · USThe University of Texas Southwestern Medical Center · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Development of a Preclinical Assay to Predict Efficacy of Ricin Toxin Subunit VaccinesR01AI125190 · NIAID · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2016 to 2020
$4.1M
NIAID NIH HHS HHSN272201400021CNIAID NIH HHS R01 AI125190NIH HHS P51 OD011104
6 · The paper itself

Abstract

Inhalation of ricin toxin (RT), a Category B biothreat agent, provokes an acute respiratory distress syndrome marked by pro-inflammatory cytokine and chemokine production, neutrophilic exudate, and pulmonary edema. The severity of RT exposure is attributed to the tropism of the toxin's B subunit (RTB) for alveolar macrophages and airway epithelial cells, coupled with the extraordinarily potent ribosome-inactivating properties of the toxin's enzymatic subunit (RTA). While there are currently no vaccines or treatments approved to prevent RT intoxication, we recently described a humanized anti-RTA IgG

Indexed as

AntibodiesBacterial toxinsVaccines

Identifiers

PMID32128254
PMCPMC7018975
OpenAlexW3006223004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.